Vertex Pharmaceuticals, Inc.

Merck Patent Gmbh

Altiris Therapeutics, Inc.

Michael P Clark

Tiansheng Wang

Upul Keerthi Bandarage

Hongbo Deng

Paul S Charifson

Francois Maltais

Mark Willem Ledeboer

Emanuele Perola

Huai Gao

John P Duffy

Brian Ledford

Wenxin Gu

Joseph M Kennedy

Ioana Davies

Luc J Farmer

Randy Scott Bethiel

Michael John Boyd

Francesco Gerald Salituro

Qing Tang

John J Court

Chao Lin

M Woods Wannamaker

Ursula A Germann

Mac Arthur Johnson, Jr

Dylan H Jacobs

Yi Zhou

Min Jiang

Steven Jones

Ann Dak-Yee Kwong

Steven M Ronkin

Randal Byrn

Nathan D Waal

David J Lauffer

Guy W Bemis

Michael Aaron Brodney

Pan Li

Dennis James Hurley

John Patrick Maxwell

Kevin Michael Cottrell

Simon Giroux

Stephen Andrew Thomson

Warren A Dorsch

Marina S Penney

Russell R Hoover

Darin Takemoto

Huijun Dong

Sarathy Kesavan

Amy Beth Hall

Rebecca Jane Swett

Timothy Lewis Tapley

Kishan Chandupatla

Michael G Natchus

Florence Fevrier Wagner

Jinwang Xu

Henry Yu

Adam R Looker

Ales Medek

Yi Shi

Ronald Lee Grey, Jr

Stefanie Roeper

Lev Tyler Dewey Fanning

Kathy Stavropoulos

Lawrence J Wilson

Kevin Gagnon

Peter D Jones

Muna Shrestha

Philip Collier

Yesim Altas Tahirovic

Diane M Boucher

Philippe Marcel Nuhant

Brad D Maxwell

Kirk Overhoff

John Wiseman

Mark A Lockwood

Setu Roday

Cavan McKeon Bligh

Robert Francis Fimognari, Jr

Veronique Damagnez

Rupa Sawant

Mariam Zaky

Sarah Carol Hood

Pedro Manuel Garcia Barrantes

Brandon C Doroh

Jason W Skudlarek

Tricia L Johnson

Shashank Kukarni

Mei-Hsiu Lai

Marisa Sposato

Siying Liu

Gabrielle Simone Fleming

Samantha Guido

Robert Daniel Giacometti

Philip N Collier

Ioana Drutu

Shashank Kulkarni

Jianglin Liang

Jun Feng

John M Wiseman

Lev Td Fanning

Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).

Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)

The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Modulators of alpha-1 antitrypsin

The present invention provides compounds of Formula I', or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Antiproliferation compounds and uses thereof

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

This invention provides methods of preparing 3-(pyrimidin-2-yl)-1H-pyrrolo[2,3-b]pyridines and 3-(pyrimidin-2-yl)-1H-pyrazolo[3,4-b]pyridines, or pharmaceutically acceptable salts thereof that are useful for inhibiting the replication of influenza viruses in a biological sample or patient, reducing the amount of influenza viruses in a biological sample or patient, and treating influenza in a patient.

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers.

Chemokine receptor modulators

Growing community of inventors

Concord, MA, United States of America

Michael P Clark